Influences of continuous steaming with black bean decoction on contents of 24 components of Polygoni Multiflori Radix

doi:10.19803/j.1672-8629.20230146

Abstract

Abstract: Objective To explore the effect of different durations of continuous steaming(0~48 h) with black bean decoction specified in “Chinese Pharmacopoeia” on the contents of main chemical components, and provide a reference for safe drug use of Polygoni Multiflori Radix(PM). Methods Pharmacopoeia-defined steamed samples were prepared before an analytical method of ultra-performance liquid chromatography with triple quadrupole mass spectrometry (UPLC-QQQ-MS/MS) was established for determination of 24 components in PM grown in Gaozhou, Guangdong Province. Results A UPLC-QQQ-MS/MS method was established for quantification of stilbene glycosides, anthraquinone, flavonoids and phenolic compounds in PM. With the extension of durations of steaming, the contents of the 24 components changed significantly. The contents of most of stilbene glycosides, anthraquinones and flavonoids decreased while those of phenolic components increased. Conclusion This method is simple, accurate and repeatable, which can be used for quantitative detection and analysis of the 24 chemical components in PM. There are strong correlations between the contents of the 24 components in PM and the durations of steaming in that the contents of stilbene glycosides, anthraquinones, flavonoids and phenols change regularly, which impact the side effects and tonic effects of PM.

Key words: Polygoni Multiflori Radix, black bean decoction, stilbene glycosides, anthraquinones, flavonoids, phenols, UPLC-QQQ-MS/MS, safety

CLC Number:

R917
R994.11

LI Yanyi, WEN Hairuo, WANG Ying, YANG Jianbo, LIU Yue, WANG Qi, ZHANG Yujie, MA Shuangcheng. Influences of continuous steaming with black bean decoction on contents of 24 components of Polygoni Multiflori Radix[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 609-615.

References

[1] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China, Volume I(中华人民共和国药典一部)[M]. Beijing: China Medical Science Press,2020:183-184.
[2] LI YY, ZHANG YJ, WANG Q, et al.Research progress on the mechanism of hepatotoxicity associated with Polygonum multiflorum Thunb.[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(6): 605-609.
[3] YANG JB, GAO WB, SUN H, et al.Research progress on material basis of liver toxicity of Polygonum multiflorum Thunb.[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(6): 610-614.
[4] XIE D, WU C, LU L, et al.Study on the hepatotoxicity of Polygonum multiflorum and its processing[J]. Journal of Chinese Medicinal Materials(中药材) , 2021, 44(3): 736-740.
[5] LIN Y, LI YM, WU P, et al.Chemical ingrediens, mechanism and prevention strategy relating to hepatotoxicity of Polygonum multiflorum Thunb.[J]. World Science and Technology-Modernization of Traditional Chinese Medicine(世界科学技术-中医药现代化), 2019, 21(9): 1862-1868.
[6] DONG LH, GUO PP, YAN WY, et al.Comparative study on hypolipidemic effect of cis-2,3,5,4’-tetrahydroxystilbene-2-O-β-D-glucoside and trans-2,3,5,4’-tetrahydroxystilbene-2-O-β-D-glucoside[J]. Journal of Shenyang Pharmaceutical University(沈阳药科大学学报), 2014, 31(12): 989-993.
[7] HE Y.Effects of Long-term Administration of Rhubarb on Colon and Its Microecology in Rats[D]. Xi’an: Northwest University, 2019.
[8] WANG Q, WEN HR, MA SC.Screening of hepatotoxic components in Polygonum multiflorum by taking FXR nuclear receptors as targets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(6): 630-634.
[9] WANG Q, YAN M, MA SC, et al.Predicting toxic monomer components in polygonum multiflorum based on quantitative structure-activity relationship[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(4): 352-355, 360.
[10] SUN M, YU QW, XIANG T, et al.2,3,5,4’-Tetrahydroxystibane-2-O-β-D-glucoside induces liver injury by disrupting bile acid homeostasis and phospholipids efflux[J]. Chinese Journal of Traditional Chinese Medicine(中国中药杂志), 2021, 46(1): 139-145.
[11] MA ZJ.Preliminary study on objectivity, clinical markers and injury mechanism of hepatotoxicity of Polygonum Multiflorum Thunb.[D]. Chengdu: Chengdu University of TCM, 2013.
[12] GAO D, LI XF, YIN P, et al.Preliminary study on hepatotoxic components in Polygoni Multiflori Radix based on processing and toxicity-decreasing[J]. Chinese Traditional and Herbal Drugs(中草药), 2017, 48(10): 2044-2050.
[13] LI XF.Study on processing and detoxification of Polygonum Multiflorum Thunb. based on integrated evaluation and control of quality, effect and application[D]. Jinan: Shandong University of Traditional Chinese Medicine, 2015.
[14] LIU YL, GAO D, LI XF, et al.Preliminary study on hepatotoxic components in Polygoni Multiflori Radix based on different adjuvants processing for detoxification[J]. Chinese Traditional and Herbal Drugs(中草药), 2020, 51(2): 330-337.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
[3]	BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.
[4]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[5]	XIONG Weiyi, REN Jingtian. Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
[6]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[7]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[8]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[9]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[10]	GAO Le, WANG Xiang, MA Jingmei, ZHANG Zezhao, WANG Xinguo, NIU Liying. Simultaneous determination of fifteen components in Xuanfudaizhe decoction by UPLC-MS/MS [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 987-991.
[11]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[12]	LIU Qian, HU Jing, LI Bo, YANG Xiaojing. Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
[13]	YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo. Risks of safety Qingkailing oral preparation [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
[14]	LI Jing, XU Ye, LIU Ranjia, PAN Chen, CUI Xiangli. Adverse reactions in patients with COVID-19 after using tocilizumab [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1049-1053.
[15]	LI Yamei, SHUI Rong. Research progress in tofacitinib for juvenile idiopathic arthritis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 956-960.